ArticleCancer chemotherapy and pharmacology2017

FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.

Y L Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.